The global community of market access professionals met in France on 2 October 2023 at the Market Access Day Paris 2023 – the first post-pandemic event of the Market Access Society (MAS).
Meriem Bouslouk-Marx presented a paper with the title ‘Case Study – Zolgensma® in Germany’. Onasemnogene abeparvovec (Zolgensma®), a gene therapy to treat the rare disease spinal muscular atrophy (SMA), served in her presentation as an example for market access and reimbursement decisions made in Germany under AMNOG.
The resolutions published by the G-BA – the decision-making Health Technology Assessment (HTA) body in Germany – on the advanced therapy medicinal product (ATMP) and orphan drug Zolgensma® illustrate the increasing complexity of the procedures for ATMPs and orphan drugs at the G-BA. The upcoming EU Joint Clinical Assessment will certainly not reduce this complexity.
Ready for MAS at the Salle Louis Liard at the Sorbonne
Meriem Bouslouk-Marx presenting at the Market Access Day